A
ALNY icon

Abingworth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Abingworth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-313,053
Closed -$9.69M – 12
2013
Q2 		$9.69M Buy
+313,053
New +$8.33M 7.45% 4

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Abingworth's ALNY Position: Q3 2013 in Review

Abingworth sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2013, closing a stake of 313,053 shares — an estimated $9.69M sold.

Abingworth first reported a position in ALNY in Q2 2013 and held it in 1 quarter. The position peaked at $9.69M in Q2 2013. 164 funds tracked by Wall St. Rank hold ALNY as of Q3 2013.

  • Abingworth reported no remaining Alnylam Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Abingworth sold 313,053 Alnylam Pharmaceuticals shares in Q3 2013, an estimated $9.69M.
  • Abingworth first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Abingworth's Alnylam Pharmaceuticals position peaked at $9.69M in Q2 2013.
  • 164 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2013.

Based on Abingworth's 13F filing for Q3 2013, filed 14 Nov 2013.